Changes in Posttreatment Spleen Volume Associated with Immunotherapy Outcomes for Advanced Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Shao YY, Wang SY, Lin SM, Diagnosis G, Systemic Therapy G. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021;120(4):1051–1060. doi:10.1016/j.jfma.2020.10.031
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070. doi:10.1056/EVIDoa2100070
   PubMedGoogle Scholar
• Rugo HS, Bardia A, Marmé F, et al. LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC). Ann Oncol. 2022;33:S808–S869.
   Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–363. doi:10.1016/j.jhep.2021.09.035
   PubMed Web of Science ®Google Scholar
• Song R, Liu F, Ping Y, Zhang Y, Wang L. Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction. Biomark Res. 2023;11(1):57. doi:10.1186/s40364-023-00498-1
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017. doi:10.1200/PO.17.00073
   PubMed Web of Science ®Google Scholar
• Shao YY, Liu TH, Hsu C, et al. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 2019;39(11):2184–2189. doi:10.1111/liv.14210
   PubMed Web of Science ®Google Scholar
• Cataldi M, Vigliotti C, Mosca T, Cammarota M, Capone D. Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes. Int J Mol Sci. 2017;18(6):1249. doi:10.3390/ijms18061249
   PubMed Web of Science ®Google Scholar
• Choi SJ, Lee SS, Jung KH, et al. Noncirrhotic portal hypertension after trastuzumab emtansine in HER2-positive breast cancer as determined by deep learning-measured spleen volume at CT. Radiology. 2022;305(3):606–613. doi:10.1148/radiol.220536
   PubMed Web of Science ®Google Scholar
• Susok L, Reinert D, Lukas C, Stockfleth E, Gambichler T. Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade. Immunotherapy. 2021;13(11):885–891. doi:10.2217/imt-2021-0022
   PubMed Web of Science ®Google Scholar
• Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28(15):2549–2555. doi:10.1200/JCO.2009.27.5701
   PubMed Web of Science ®Google Scholar
• Castagnoli F, Doran S, Lunn J, et al. Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. PLoS One. 2022;17(7):e0270950. doi:10.1371/journal.pone.0270950
   PubMedGoogle Scholar
• Muller L, Gairing SJ, Kloeckner R, et al. Baseline splenic volume outweighs immuno-modulated size changes with regard to survival outcome in patients with hepatocellular carcinoma under immunotherapy. Cancers. 2022;14(15):3574. doi:10.3390/cancers14153574
   PubMed Web of Science ®Google Scholar
• Ren Z, Ducreux M, Abou-Alfa GK, et al. Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, Phase 2 trial. Liver Cancer. 2023;12(1):72–84. doi:10.1159/000527175
   PubMed Web of Science ®Google Scholar
• Shao YY, Cheng AL, Hsu CH. An underdiagnosed hypothyroidism and its clinical significance in patients with advanced hepatocellular carcinoma. Oncologist. 2021;26(5):422–426. doi:10.1002/onco.13755
   PubMed Web of Science ®Google Scholar
• Bezerra AS, D’Ippolito G, Faintuch S, Szejnfeld J, Ahmed M. Determination of splenomegaly by CT: is there a place for a single measurement? AJR Am J Roentgenol. 2005;184(5):1510–1513. doi:10.2214/ajr.184.5.01841510
   PubMed Web of Science ®Google Scholar
• Prassopoulos P, Daskalogiannaki M, Raissaki M, Hatjidakis A, Gourtsoyiannis N. Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol. 1997;7(2):246–248. doi:10.1007/s003300050145
   PubMed Web of Science ®Google Scholar
• Ugel S, Peranzoni E, Desantis G, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012;2(3):628–639. doi:10.1016/j.celrep.2012.08.006
   PubMed Web of Science ®Google Scholar
• Markel JE, Noore J, Emery EJ, Bobnar HJ, Kleinerman ES, Lindsey BA. Using the spleen as an in vivo systemic immune barometer alongside osteosarcoma disease progression and immunotherapy with α-PD-L1. Sarcoma. 2018;2018:8694397. doi:10.1155/2018/8694397
   PubMedGoogle Scholar
• Sato-Kaneko F, Yao S, Ahmadi A, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2(18):e93397. doi:10.1172/jci.insight.93397
   PubMed Web of Science ®Google Scholar
• Ji C, Roy MD, Golas J, et al. Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clin Cancer Res. 2019;25(15):4735–4748. doi:10.1158/1078-0432.CCR-18-4083
   PubMed Web of Science ®Google Scholar
• Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. J Immunother Cancer. 2019;7(1):82. doi:10.1186/s40425-019-0551-y
   PubMedGoogle Scholar
• Seith F, Forschner A, Weide B, et al. Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer. 2020;8(2):e000656. doi:10.1136/jitc-2020-000656
   PubMed Web of Science ®Google Scholar
• Aslan V, Karabörk Kılıç AC, Özet A, et al. The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma. BMC Cancer. 2023;23(1):1045. doi:10.1186/s12885-023-11558-y
   PubMed Web of Science ®Google Scholar
• Armstrong S, Roy T, Singh B, et al. TKIs beyond immunotherapy predict improved survival in advanced HCC. J Cancer Res Clin Oncol. 2023;149(6):2559–2574. doi:10.1007/s00432-022-04115-w
   PubMed Web of Science ®Google Scholar
• Chen BB, Liang PC, Shih TT, et al. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. Eur Radiol. 2023;33(1):512–522. doi:10.1007/s00330-022-08980-4
   PubMed Web of Science ®Google Scholar
• Jiang Y, Tu X, Zhang X, et al. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. Support Care Cancer. 2020;28(11):5569–5579. doi:10.1007/s00520-020-05478-x
   PubMed Web of Science ®Google Scholar
• Takeishi K, Kawanaka H, Itoh S, et al. Impact of splenic volume and splenectomy on prognosis of hepatocellular carcinoma within Milan criteria after curative hepatectomy. World J Surg. 2018;42(4):1120–1128. doi:10.1007/s00268-017-4232-z
   PubMed Web of Science ®Google Scholar
• Bae JS, Lee DH, Yoo J, et al. Association between spleen volume and the post-hepatectomy liver failure and overall survival of patients with hepatocellular carcinoma after resection. Eur Radiol. 2021;31(4):2461–2471. doi:10.1007/s00330-020-07313-7
   PubMed Web of Science ®Google Scholar
• Wu WC, Chiou YY, Hung HH, et al. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol. 2012;46(9):789–795. doi:10.1097/MCG.0b013e31825ceeb5
   PubMed Web of Science ®Google Scholar
• Müller L, Kloeckner R, Mähringer-Kunz A, et al. Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. Eur Radiol. 2022;32(9):6302–6313. doi:10.1007/s00330-022-08737-z
   PubMed Web of Science ®Google Scholar
• Jung EJ, Ryu CG, Kim G, et al. Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma. Anticancer Res. 2012;32(8):3357–3362.
   PubMed Web of Science ®Google Scholar
• Kosmin M, Makris A, Jawad N, Woolf D, Miles D, Padhani AR. Splenic enlargement and bone marrow hyperplasia in patients receiving trastuzumab-emtansine for metastatic breast cancer. Target Oncol. 2017;12(2):229–234. doi:10.1007/s11523-017-0477-6
   PubMed Web of Science ®Google Scholar
• Iranmanesh P, Vazquez O, Terraz S, et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma. J Hepatol. 2014;60(5):969–974. doi:10.1016/j.jhep.2013.12.015
   PubMed Web of Science ®Google Scholar
• Lee CM, Lee SS, Choi WM, et al. An index based on deep learning-measured spleen volume on CT for the assessment of high-risk varix in B-viral compensated cirrhosis. Eur Radiol. 2021;31(5):3355–3365. doi:10.1007/s00330-020-07430-3
   PubMed Web of Science ®Google Scholar